Playback speed
10 seconds
ESMO 2023 Insights: "Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent/Metastatic Cervical Cancer"
By
ecancer
FEATURING
Ignace Vergote
By
ecancer
FEATURING
Ignace Vergote
69 views
November 13, 2023
Login to view comments.
Click here to Login